Helicobacter pylori Between Scientific Reality and Commercial Exaggeration: A Critical Perspective in Modern Medicine

Introduction

Over the past decades, modern medicine has witnessed several paradigm-shifting discoveries, among which the identification of Helicobacter pylori (H. pylori) as a causative agent of peptic ulcer disease stands as a landmark achievement. However, this scientific breakthrough has gradually evolved from a knowledge revolution into a commercialized medical phenomenon, with diagnostic and therapeutic practices expanding far beyond actual clinical necessity.

This article aims to provide a balanced critical analysis of the current clinical role of H. pylori and to highlight the phenomenon of disease exaggeration driven by pharmaceutical and commercial influences.

H. pylori: Prevalence Versus Disease

Epidemiological studies indicate that more than half of the world's population carries H. pylori, with prevalence reaching 70-80% in developing countries. Nevertheless, only 10-15% of infected individuals develop peptic ulcer disease, while the incidence of gastric cancer remains below 2%.

These figures raise fundamental questions about current clinical practice that treats the mere presence of H. pylori as a disease requiring eradication, regardless of clinical context or risk stratification.

Inflated Clinical Role of H. pylori

Following the establishment of the causal relationship between H. pylori and peptic ulcer disease, the bacterium rapidly became a universal explanation for upper gastrointestinal symptoms. Dyspepsia, epigastric pain, and heartburn are frequently attributed to H. pylori without adequate clinical assessment.

• Excessive use of diagnostic tests (breath tests and stool antigen tests)
• Routine prescription of triple or quadruple antibiotic therapies without proper indication
• Neglect of other common etiologies such as NSAIDs, physiological stress, and smoking

The Commercial Influence of the Pharmaceutical Industry

The expansion of H. pylori eradication therapies represents a multibillion-dollar pharmaceutical market, with frequent updates of treatment guidelines and aggressive marketing of new drug combinations.

• Increasing antibiotic resistance, particularly to clarithromycin, metronidazole, and levofloxacin
• Rising treatment costs and increasingly complex regimens
• Transformation of targeted therapy into routine mass treatment

Changing Etiology of Peptic Ulcer Disease

Clinical experience and recent data suggest that the etiological landscape of peptic ulcer disease has shifted. Non-steroidal anti-inflammatory drugs, aspirin, and stress-related mucosal disease in critically ill patients have become leading causes, while the relative contribution of H. pylori has declined in certain populations.

This trend necessitates a re-evaluation of traditional paradigms that place H. pylori at the center of peptic ulcer pathology.

Real Risk Versus Overstatement

Despite the critique above, the carcinogenic role of H. pylori cannot be ignored. It is classified as a Class I carcinogen and is associated with MALT lymphoma, chronic atrophic gastritis, and intestinal metaplasia.

However, clinical management should shift from a universal eradication policy to risk-based, precision medicine approaches.

Toward a Balanced Clinical Practice

Modern clinical practice must transition from a treat-all model to an evidence-based, risk-stratified approach that balances:

• Therapeutic benefits
• Antibiotic resistance risks
• Economic burden
• Patient quality of life

Medical decision-making should remain independent of commercial pressures and grounded in scientific evidence and ethical responsibility.

Conclusion

H. pylori is neither a myth nor a clinical villain, but it represents a compelling example of how scientific discoveries can be transformed into consumer-driven medical phenomena when knowledge intersects with pharmaceutical markets. Restoring balance between science, clinical practice, and commercial interests remains a major challenge for healthcare systems in the 21st century.